These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 33383214)

  • 61. Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.
    Tsilimigras DI; Mehta R; Paredes AZ; Moris D; Sahara K; Bagante F; Ratti F; Marques HP; Silva S; Soubrane O; Lam V; Poultsides GA; Popescu I; Grigorie R; Alexandrescu S; Martel G; Workneh A; Guglielmi A; Hugh T; Aldrighetti L; Endo I; Spolverato G; Umberto C; Pawlik TM
    Ann Surg; 2020 Oct; 272(4):574-581. PubMed ID: 32932309
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
    Margonis GA; Boerner T; Bachet JB; Buettner S; Moretto R; Andreatos N; Sartore-Bianchi A; Wang J; Kamphues C; Gagniere J; Lonardi S; Løes IM; Wagner D; Spallanzani A; Sasaki K; Burkhart R; Pietrantonio F; Pikoulis E; Pawlik TM; Truant S; Orlandi A; Pikouli A; Pella N; Beyer K; Poultsides G; Seeliger H; Aucejo FN; Kornprat P; Kaczirek K; Lønning PE; Kreis ME; Wolfgang CL; Weiss MJ; Cremolini C; Benoist S; D'Angelica M
    Ann Surg; 2023 Sep; 278(3):e540-e548. PubMed ID: 36453261
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
    Bachet JB; Moreno-Lopez N; Vigano L; Marchese U; Gelli M; Raoux L; Truant S; Laurent C; Herrero A; Le Roy B; Deguelte Lardiere S; Passot G; Hautefeuille V; De La Fouchardiere C; Artru P; Ameto T; Mabrut JY; Schwarz L; Rousseau B; Lepère C; Coriat R; Brouquet A; Sa Cunha A; Benoist S
    Br J Surg; 2019 Aug; 106(9):1237-1247. PubMed ID: 31183866
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis.
    Wang K; Xu D; Yan XL; Poston G; Xing BC
    Eur J Surg Oncol; 2018 Jun; 44(6):771-777. PubMed ID: 29580735
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
    Yonekawa Y; Uehara K; Mizuno T; Aiba T; Ogura A; Mukai T; Yokoyama Y; Ebata T; Kodera Y; Nagino M
    Int J Clin Oncol; 2021 Jan; 26(1):126-134. PubMed ID: 33074351
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Machine Learning Approach to Stratifying Prognosis Relative to Tumor Burden after Resection of Colorectal Liver Metastases: An International Cohort Analysis.
    Paro A; Hyer MJ; Tsilimigras DI; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Aucejo F; Cloyd JM; Pawlik TM
    J Am Coll Surg; 2022 Apr; 234(4):504-513. PubMed ID: 35290269
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term and perioperative outcomes of laparoscopic versus open liver resection for colorectal liver metastases with propensity score matching: a multi-institutional Japanese study.
    Beppu T; Wakabayashi G; Hasegawa K; Gotohda N; Mizuguchi T; Takahashi Y; Hirokawa F; Taniai N; Watanabe M; Katou M; Nagano H; Honda G; Baba H; Kokudo N; Konishi M; Hirata K; Yamamoto M; Uchiyama K; Uchida E; Kusachi S; Kubota K; Mori M; Takahashi K; Kikuchi K; Miyata H; Takahara T; Nakamura M; Kaneko H; Yamaue H; Miyazaki M; Takada T
    J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):711-20. PubMed ID: 25902703
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of tumour size ratio on liver recurrence-free survival of patients undergoing hepatic resection for colorectal liver metastases.
    Zhai Y; Bai W; Zhou J; Dong Q; Zhang J
    BMC Cancer; 2022 Jan; 22(1):103. PubMed ID: 35078439
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis.
    Gau L; Ribeiro M; Pereira B; Poirot K; Dupré A; Pezet D; Gagnière J
    Eur J Surg Oncol; 2021 Nov; 47(11):2722-2733. PubMed ID: 34099355
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The prognostic impact of resection margin status varies according to the genetic and morphological evaluation (GAME) score for colorectal liver metastasis.
    Wang HW; Wang LJ; Jin KM; Bao Q; Li J; Wang K; Xing BC
    J Surg Oncol; 2021 Sep; 124(4):619-626. PubMed ID: 34081792
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
    O Connor JM; Sanchez Loria F; Ardiles V; Grondona J; Sanchez P; Andriani O; Fauda M; Brancato F; Huertas E; Alvarez F; de Santibañes E
    Future Oncol; 2019 Sep; 15(27):3149-3157. PubMed ID: 31426677
    [No Abstract]   [Full Text] [Related]  

  • 74. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
    Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
    J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
    Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
    Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Potential for cure and predictors of long-term survival after radiofrequency ablation for colorectal liver metastases: A 20-years single-center experience.
    Weilert H; Sadeghi D; Lipp M; Oldhafer KJ; Donati M; Stang A
    Eur J Surg Oncol; 2022 Dec; 48(12):2487-2494. PubMed ID: 35718675
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
    John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
    Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches.
    Roncato R; Polesel J; Tosi F; Peruzzi E; Brugugnoli E; Pantano CL; Furfaro M; Girolamo FD; Nani A; Pani A; Milan N; DE Mattia E; Sartore-Bianchi A; Cecchin E
    Oncol Res; 2024; 32(9):1407-1422. PubMed ID: 39220128
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
    Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.